Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
about
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
description
scientific article published on 13 December 2018
@en
name
Pegbelfermin (BMS-986036), a P ...... ebo-controlled, phase 2a trial
@en
type
label
Pegbelfermin (BMS-986036), a P ...... ebo-controlled, phase 2a trial
@en
prefLabel
Pegbelfermin (BMS-986036), a P ...... ebo-controlled, phase 2a trial
@en
P2093
P1433
P1476
Pegbelfermin (BMS-986036), a P ...... ebo-controlled, phase 2a trial
@en
P2093
Arun Sanyal
Brent A Neuschwander-Tetri
Dina Halegoua-DeMarzio
Edgar D Charles
Eric J Lawitz
Rohit Loomba
Rose Christian
Stephanie Noviello
Stephen A Harrison
Sudeep Kundu
P304
P356
10.1016/S0140-6736(18)31785-9
P577
2018-12-13T00:00:00Z